The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

Cellular and Molecular Life Sciences

Volumn 63, Issue 7-8, 2006, Pages 832-842

  Dixit, N M ^a   Perelson, A S ^b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Combination therapy; Mathematical model; Monotherapy; Mutagenesis; Treatment response; Viral dynamics

Indexed keywords

ALANINE AMINOTRANSFERASE; INOSINATE DEHYDROGENASE; INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DOWN REGULATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; ERYTHROCYTE LIFESPAN; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; MATHEMATICAL MODEL; MONOTHERAPY; NONHUMAN; PREDICTION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; RNA REPLICATION; RNA STRUCTURE; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VIRION; VIRUS INDUCTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 33646560284     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5455-y     Document Type: Review

References (97)

1. Witkoswski J. T., Robins R. K., Sidwell R. W. and Simon L. N. (1972) Design, synthesis and broad spectrum antiviral activity of 1-β-D- Ribofuranosyl-1, 2,4-triazole-3-carboxamide and related nucleosides. J. Med. Chem. 15: 1150-1154
2. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T. and Robins R. K. (1972) Broad spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide. Science 177: 705-706
3. Sidwell R. W. (1980) Ribavirin: In vitro antiviral activity. In: Ribavirin: A Broad Spectrum Antiviral Agent, pp. 23-42, Smith R. A. and Kirkpatrick W. (eds.), Academic Press, London
4. Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K. et al. (1973) Mechanism of action of 1-β-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70: 1174-1178
5. Allen L. B. (1980) Review of in vivo efficacy of ribavirin. In: Ribavirin: A Broad Spectrum Antiviral Agent, pp. 43-58, Smith R. A. and Kirkpatrick W. (eds.), Academic Press, London
6. World Health Organization (2000) Hepatitis C - global prevalence (update). World Health Org. Weekly Epidemiol. Rec. 75: 18-19
7. Hoofnagle J. H. (2002) Course and outcome of hepatitis C. Hepatology 36: S21-S29
8. Di Bisceglie A. M. and Hoofnagle J. H. (2002) Optimal therapy of hepatitis C. Hepatology 36: S121-S127
9. Di Bisceglie A. M., Conjeevaram H. S., Fried M. W., Sallie R., Park Y., Yurdaydin C. et al. (1995) Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123: 897-903
10. Hoofnagle J. H., Lau D., Conjeevaram H., Kleiner D. and Di Bisceglie A. M. (1996) Prolonged therapy of chronic hepatitis C with ribavirin. J. Viral Hepat. 3: 247-252
11. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A. et al. (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25: 591-598
12. Bodenheimer H. C. Jr., Lindsay K. L., Davis G. L., Lewis J. H., Thung S. N. and Seeff L. B. (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 26: 473-477
13. Zoulim F., Haem J., Ahmed S. S., Chossegros P., Habersetzer F., Chevallier M. et al. (1998) Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J. Viral Hepat. 5, 193-198
14. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Rustgi V. K. et al. (1998) Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339: 1485-1492
15. Reichard O., Norkrans G., Fryden A., Braconier J. H., Sonnerborg A. and Weiland O. (1998) Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 351: 83-87
16. Poynard T., Marcellin P., Lee S. S., Niederau C., Minuk G. S. and Ideo G. (1998) Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-1432
17. Feld J. J. and Hoofnagle J. H. (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972
18. National Institutes of Health. (2002) Consensus Statement on Management of Hepatitis C. NIH Consens. State Sci. Statements 19: 1-46
19. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M. Reindollar R. et al. (2001) Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965
20. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales F. L. Jr. et al. (2002) Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982
21. Tan S.-L., Pause A., Shi Y. and Sonenberg N. (2002) Hepatitis C therapeutics: Current status and emerging strategies. Nat. Rev. Drug Discov. 1: 867-881
22. De Francesco R. and Migliaccio G. (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436: 953-960
23. Houghton M. and Abrignani S. (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436: 961-966
24. Hoofnagle J. H., Ghany M. G., Kleiner D. E., Doo E., Heller T., Promrat K. et al. (2003) Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 38: 66-74.
25. Lau J. Y. N., Tam R. C., Liang T. J. and Hong Z. (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009
26. Parker W. B. (2005) Metabolism and antiviral activity of ribavirin. Virus Res. 107: 165-171
27. Glue P. (1999) The clinical pharmacology of ribavirin. Semin. Liv. Dis. 19: 17-24
28. Dixit N. M., Layden-Almer J. E., Layden T. J. and Perelson A. S. (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924
29. Bartenschlager R. (2002) Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug. Discov. 1: 911-916
30. Chisari F. V. (2005) Unscrambling hepatitis C virus-host interactions. Nature 436: 930-932.
31. Lindenbach B. D. and Rice C. M. (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436: 933-938
32. Neumann A. U., Lam N. P., Dahari H., Gretch D. R., Wiley T. E., Layden T. J. et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103-107
33. Lau D. T., Kleiner D. E., Ghany M. G., Park Y., Schmid P. and Hoofnagle J. H. (1998) 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28: 1121-1127
34. Smith R. A. (1980) Mechanisms of action of ribavirin. In: Ribavirin: A Broad Spectrum Antiviral Agent, pp. 99-118, Smith R. A. and Kirkpatrick W. (eds.), Academic Press, London
35. Zhang Y., Jamaluddin M., Wang S., Tian B., Garofalo R. P. and Casola A. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77: 5933-5947
36. Buckwold V. E., Wei J., Wenzel-Mathers M. and Russell J. (2003) Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 47: 2293-2298.
37. Smith R. A. (1984) Background and mechanisms of action of ribavirin. In: Clinical Applications of Ribavirin, pp. 1-18, Smith R. A., Knight V. and Smith J. A. D. (eds.), Academic Press, Florida
38. Crotty S., Maag D., Arnold J. J., Zhong W., Lau J. Y., Hong Z. et al. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6: 1375-1379
39. Crotty S., Cameron C. E. and Andino R. (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. USA 98: 6895-6900
40. Maag D., Castro C., Hong Z. and Cameron C. E. (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276: 46094-46098
41. Eriksson B., Helgstrand E., Johansson N. G., Larsson A., Misiorny A., Noren J. O. et al. (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11: 946-951
42. Wray S. K., Gilbert B. E. and Knight V. (1985) Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5: 39-48
43. Toltzis P., O'Connell K. and Patterson J. L. (1988) Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32: 492-497
44. Fernandez-Larsson R., O'Connell K., Koumans E. and Patterson J. L. (1989) Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob. Agents Chemother. 33: 1668-1673
45. Rankin Jr. J. T., Eppes S. B., Antczak J. B. and Joklik W. K. (1989) Studies on the mechanism of the antiviral activity of ribavirin against reovirus, Virology 168: 147-158
46. Bougie I. and Bisaillon M. (2003) Initial binding of the broad-spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J. Biol. Chem. 278: 52471-52478
47. Vo N. V., Young K. C. and Lai M. M. C. (2003) Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42: 10462-10471
48. Laxton C., Gilbert S., Sully R., Smith K., Thornberry A., Wilkinson T. et al. (2000) Characterization of interferon-alfa-2a and pegylated interferon-alfa-2a in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication. (Abstract) 7th International Meeting on Hepatitis and Related Viruses, pp. 338
49. Pawlotsky J. M., Dahari H., Neumann A. U., Hezode C., Germanidis G., Lonjon I. et al. (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126: 703-714
50. Layden-Almer J. E., Ribeiro R. M., Wiley T., Perelson A. S. and Layden T. J. (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37: 1343-1350
51. Herrmann E., Lee J.-H., Marison G., Modi M. and Zeuzem S. (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358
52. Sintchak M. D. and Nimmesgern E. (2000) The structure of insosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47: 163-184
53. Lowe J. K., Brox L. and Henderson J. F. (1977) Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res. 37: 736-743
54. Muller W. E. G., Maidhof A., Taschner H. and Zahn R. K. (1977) Virazole (1-β-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide): a cytostatic agent. Biochem. Pharmacol. 26: 1071-1075
55. Zimmerman T. P. and Deeprose R. D. (1978) Metabolism of 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide and re-lated five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cells. Biochem. Pharmacol. 27: 709-716
56. Balzarini J., Lee C. K., Herdewijn P. and De Clercq E. (1991) Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. 266: 21509-21514
57. Balzarini J., Karlsson A., Wang L., Bohman C., Horska K., Votruba I. et al. (1993) EICAR (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide): a novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268: 24591-24598
58. Pankiewicz K. W., Lesiak-Watanabe K., Watanabe K. A. and Malinowski K. (1999) Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. Curr. Med. Chem. 6: 629-634.
59. Markland W., McQuaid T. J., Jain J. and Kwong A. D. (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44: 859-866
60. Tam R. C., Pai B., Bard J., Lim C., Averett D. R., Phan U. T. et al. (1999) Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30: 376-382
61. Peavy D. L., Powers C. N. and Knight V. (1981) Inhibition of plaque-forming cell responses in vivo by ribavirin. J. Immunol. 126: 861-864
62. Edell D., Brice E., Hale K., Edell D. and Khoshoo, V. (1998) Reduced long term respiratory morbidity after treatment of respiratory syncytial virus bronchiolits with ribavirin in previously healthy infants: a preliminary report. Pediatric Pulmonol. 25: 154-158.
63. Cramp M. E., Rossol S., Chokshi S., Carucci P., Williams R. and Naoumov N. V. (2000) Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118: 346-355
64. Domingo E., Escarmis C., Sevilla N., Moya A., Elena S. F., Quer J. et al. (1996) Basic concepts in RNA virus evolution. FASEB J. 10: 859-864
65. Eigen M., McCaskill J. and Schuster P. (1989) The molecular quasi-species. Adv. Chem. Phys. 75: 149-263
66. Eigen M., McCaskill J. and Schuster, P. (1988) Molecular quasi-species. J. Phys. Chem. 92: 6881-6891
67. Eigen M. (2002) Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. USA 99:13374-13376
68. Vignuzzi M., Stone J. K. and Andino R. (2005) Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107: 173-181
69. Severson W. E., Schmaljohn C. S., Javadian A. and Jonsson C. B. (2003) Ribavirin causes error catastrophe during hantaan virus replication. J. Virol. 77: 481-488
70. Lanford R. E., Guerra B., Lee H., Averett D. R., Pfeiffer B., Chavez D. et al. (2003) Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77: 1092-1104
71. Contreras A. M., Hiasa Y., He W., Terella A., Schmidt E. V. and Chung R. T. (2002) Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76: 8505-8517
72. Zhou S., Liu R., Baroudy B. M., Malcolm B. A. and Reyes G. R. (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310: 333-342
73. Airaksinen A., Pariente N., Menendez-Arias L. and Domingo E. (2003) Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311: 339-349
74. Lanford R. E., Chavez D., Guerra B., Lau J. Y., Hong Z., Brasky K. M. et al. (2001) Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75: 8074-8081
75. Hong Z. (2003) The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology 38: 807-810
76. Young K. C., Lindsay K. L., Lee K. J., Liu W. C., He J. W., Milstein S. L. et al. (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38: 869-878
77. Lutchman G. A., Danehower S., Park Y., Ward C., Liang J. T., Hoofnagle J. H. et al. (2004) Mutation rate of hepatitis C virus inpatients during ribavirin montherapy. Hepatology 41: 385A
78. Asahina Y., Izumi N., Enomoto N., Uchihara M., Kurosaki M., Onuki Y. et al. (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43: 623-629
79. Perelson A. S. and Ribeiro R. M. (2005) Mutagenic effects of ribavirin in vivo. J. Hepatol. 43: 553-555
80. Tsubota A., Akuta N., Suzuki F., Suzuki Y., Someya T., Kobayashi M. et al. (2002) Viral dynamics and pharmacokinetics in combined interferon α-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 45: 33-42
81. Arase Y., Ikeda K., Tsubota A., Suzuki F., Suzuki Y., Saitoh S. et al. (2005) Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48: 138-144
82. Lindahl K., Stahle L., Bruchfeld A. and Schvarz R. (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41: 275-279.
83. 14C- Ribavirin: distribution and pharmacokinetic studies in rats, baboons and man. In: Ribavirin: A Broad Spectrum Antiviral Agent, pp. 83-98, Smith R. A. and Kirkpatrick W. (eds.), Academic Press, London
84. Glue P., Schenker S., Gupta S., Clement R. P., Zambas D. and Salfi M. (2000) The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br. J. Clin. Pharmacol. 49: 417-421
85. Khakoo S., Glue P., Grellier L., Wells B., Bell A., Dash C. et al. (1998) Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46: 563-570
86. Preston S. L., Drusano G. L., Glue P., Nash J., Gupta S. K. and McNamara P. (1999) Pharmacokinetcs and absolute bioavailability of ribavirin in healthy volunteers as determined by subisotope methodology. Antimicrobial Agents Chemother. 43: 2451-2456
87. 14C]ribavirin in rats and cynomulgus monkeys. Antimicrobial Agents Chemother. 47: 1395-1398
88. +- nucleoside purine (N1) transporter. Pharm. Res. 15: 950-952
89. Jarvis S. J., Thorn J. A. and Glue P. (1998) Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensetive (es)-nucleoside transporters. Br. J. Clin. Pharmacol. 123: 1587-1592
90. Galois-Montbrun S., Chen Y., Dutartre H., Sophys M., Morera S., Guerreiro C. et al. (2003) Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. Mol. Pharmacol. 63: 538-546
91. Page T. and Connor J. D. (1990) The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22: 379-383
92. Shulman N. R. (1984) Assessment of hematological effects of ribavirin in humans. In: Clinical Applications of Ribavirin, Smith R. A., Knight V. and Smith J. A. D. (eds.) pp. 79-92, Academic Press, New York
93. Welling P. G. (1986) Pharmacokinetics: Processes and Mathematics, American Chemical Society, Washington, DC
94. Gabrielson J. and Weiner D. (2000) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm
95. Powers K. A., Dixit N. M., Ribeiro R. M., Golia P., Talal A. H. and Perelson A. S. (2003) Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon α-2b. Semin. Liv. Dis. 23: 13-18
96. Smith R. A. and Kirkpatrick W. (1980) Ribavirin: A Broad Spectrum Antiviral Agent, Academic Press, London
97. Ribeiro R. M., Layden-Almer J., Powers K. A., Layden T. J. and Perelson A. S. (2003) Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 38: 509-517